ArticleJournal of vascular surgery. Venous and lymphatic disorders2026
Thirty-day rehospitalization after saphenous vein treatment in France: A nationwide observational study.
Article in Journal of vascular surgery. Venous and lymphatic disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEndovenous thermal ablation (EVTA) has become increasingly used for treatment of saphenous vein incompetence. However, severe adverse events leading to rehospitalization remain insufficiently characterized in large real-world populations. This study aimed to evaluate 30-day rehospitalization after great saphenous vein (GSV) and small saphenous vein (SSV) interventions in France and compare outcomes between EVTA and surgery.
methodsWe conducted a nationwide observational study using the French National Health Data System (Système National des Données de Santé). Adult patients undergoing GSV or SSV intervention between January 2020 and November 2024 were identified using International Classification of Diseases, 10th Revision and Common Classification of Medical Acts. The primary outcome was all-cause 30-day rehospitalization after discharge. Secondary outcomes included rehospitalization for thromboembolic events, major bleeding, infection, and other procedure-related complications. Multivariable logistic regression analyses were performed to identify factors associated with rehospitalization.
resultsA total of 450,202 patients underwent saphenous vein intervention, including 65,485 SSV and 384,717 GSV procedures. EVTA represented 77.3% of SSV interventions and 83.4% of GSV interventions. Thirty-day rehospitalization occurred in 1.2% of patients after SSV treatment and 4.3% after GSV treatment. Rehospitalizations due to thromboembolic complications were exceptionally rare (0.01% after SSV treatment and 0.03% after GSV treatment), whereas major bleeding and infectious complications were nearly absent. For SSV interventions, treatment modality was not independently associated with rehospitalization after adjustment. For GSV interventions, surgery was associated with a lower risk of 30-day rehospitalization compared with EVTA (adjusted odds ratio, 0.54; 95% confidence interval, 0.41-0.71). Among patients treated with EVTA for GSV incompetence, no difference was observed between endovenous laser ablation and radiofrequency ablation (adjusted odds ratio, 0.97; 95% confidence interval, 0.81-1.16).
conclusionsIn this nationwide French cohort, 30-day rehospitalization after saphenous vein intervention was uncommon, and severe complications requiring rehospitalization were exceptionally rare. EVTA was the predominant treatment modality and demonstrated an excellent safety profile. Rehospitalization appeared to be influenced primarily by patient characteristics rather than major procedure-related complications, supporting the safety of contemporary treatment strategies for both GSV and SSV incompetence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.